Zobrazeno 241 - 250
of 6 584
pro vyhledávání: ''
Autor:
Wei Xie, Philipp W. Raess, Jennifer Dunlap, Cristina Magallanes Hoyos, Hongmei Li, Peng Li, Ronan Swords, Susan B. Olson, Fei Yang, Tauangtham Anekpuritanang, Shimin Hu, Joanna Wiszniewska, Guang Fan, Richard D. Press, Stephen R. Moore
Publikováno v:
Leukemia & Lymphoma. 63:1907-1916
Autor:
Molly E. Graveno, Alison Carulli, Craig W. Freyer, Brendan L. Mangan, Robert Nietupski, Alison W. Loren, Noelle V. Frey, David L. Porter, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Daria V. Babushok, Keith W. Pratz
Publikováno v:
Leukemia & Lymphoma. 63:1645-1650
Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve
Autor:
James P. Collard, Mary K. McKenna, Sunil K. Noothi, Sara S. Alhakeem, Jacqueline R. Rivas, Vivek M. Rangnekar, Natarajan Muthusamy, Subbarao Bondada
Publikováno v:
Leukemia & Lymphoma. 63:1810-1822
The chronic lymphocytic leukemia (CLL) microenvironment has been receiving an increasing amount of attention, but there is currently limited data surrounding how the microenvironment affects initial development of CLL. We determined that the spleen i
Autor:
Ruben Mesa, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Jeanne Palmer, Uwe Platzbecker, Jacek Treliński, Kazuya Shimoda, Rafe Donahue, Koenraad D’Hollander, Mark Kowalski, Srdan Verstovsek
Publikováno v:
Leukemia & Lymphoma. 63:1718-1722
ispartof: LEUKEMIA & LYMPHOMA vol:63 issue:7 pages:1718-1722 ispartof: location:United States status: published
Autor:
Nasr Eshibona, Abdulazeez Giwa, Sophia Catherine Rossouw, Junaid Gamieldien, Alan Christoffels, Hocine Bendou
Publikováno v:
Leukemia & Lymphoma. 63:1897-1906
Autor:
James Collins, Sarah E. Stump, Hillary Heiling, Michele Muir, Allison Deal, Darrian Proco, Catharine Nguyen, Monica Cozad, Anthony Mato, Catherine C. Coombs, Benyam Muluneh
Publikováno v:
Leukemia & Lymphoma. 63:1823-1830
Ibrutinib is an oral Bruton's tyrosine kinase inhibitor approved for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Clinical trial data suggest that strict adherence is directly related to clinical outcomes. Thi
Autor:
Guillermo Garcia-Manero, Vincent Ribrag, Yayan Zhang, Mohammed Farooqui, Patricia Marinello, B. Douglas Smith
Publikováno v:
Leukemia & Lymphoma. 63:1660-1668
The phase 1b multicohort KEYNOTE-013 study assessed the safety and antitumor activity of pembrolizumab given at 10 mg/kg/day every 2 weeks for up to 2 years in hematologic malignancies, including myelodysplastic syndromes (MDS) refractory to a hypome
Publikováno v:
Leukemia & Lymphoma. 63:3268-3270
Autor:
Luke Carter-Brzezinski, Elizabeth Davies, Jane Norman, Lourdes Rubio, Christopher Dixon, Sarah Brett, Tony Dunne, Shahid Iqbal, Fiona L. Dignan, Shazaad Ahmad, Nicholas Machin, Henry Morriss, Anthony Wilson, Eleni Tholouli
Publikováno v:
Leukemia & Lymphoma. 63:3265-3267
Autor:
Ginevra Lolli, Margherita Ursi, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Lisa Argnani, Francesca Bonifazi, Pier Luigi Zinzani
Publikováno v:
Leukemia & Lymphoma. 63:3012-3014